The rule eliminates rebates drugmakers pay to pharmacy benefit managers. It was intended by HHS to simplify the drug-pricing system and to pass discounts to consumers. Drugmakers have supported the rule, but most pharmacy benefit managers oppose it.
PCMA argues that the rule will drastically increase Medicare Part D premiums and costs for taxpayers.
“[HHS] failed to consider the significant impacts on beneficiaries and government costs that were articulated in thousands of public comments opposing the rule when it was originally proposed. The rebate rule cannot be implemented and should be invalidated,” PCMA’s president and CEO, J.C. Scott, said in a news release.
The group also said that rebates lower Medicare costs, the rebate rule would cost taxpayers $177 billion over 10 years, and that it doesn’t address prescription drug list prices.
Read PCMA’s full statement here.
More articles on pharmacy:
Eli Lilly antibody drug likely effective against UK virus strain, but not South African variant, CEO says
West Virginia county health department banned from giving COVID-19 vaccines
Moderna vaccine should protect against COVID-19 at least a year, CMO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.